{
    "organizations": [],
    "uuid": "e74874121d4641f5dcbfecb1ed54f3d68203799f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ionis-and-astrazeneca-advance-new/brief-ionis-and-astrazeneca-advance-new-drug-for-nash-idUSFWN1RM0MC",
    "ord_in_thread": 0,
    "title": "BRIEF-Ionis And AstraZeneca Advance New Drug For NASH",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Ionis Pharmaceuticals Inc:\n* IONIS AND ASTRAZENECA ADVANCE NEW DRUG FOR NASH * IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX\n* IONIS PHARMACEUTICALS INC - ASTRAZENECA WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT & COMMERCIALIZATION OF IONIS-AZ6-2.5-LRX\n* IONIS PHARMACEUTICALS INC - AS IONIS-AZ6-2.5-LRX ADVANCES, CO MAY RECEIVE UP TO $300 MLN IN ADDITIONAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-09T19:16:00.000+03:00",
    "crawled": "2018-04-10T12:41:01.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "ionis",
        "pharmaceutical",
        "inc",
        "ionis",
        "astrazeneca",
        "advance",
        "new",
        "drug",
        "nash",
        "ionis",
        "pharmaceutical",
        "inc",
        "earns",
        "mln",
        "license",
        "fee",
        "rx",
        "ionis",
        "pharmaceutical",
        "inc",
        "astrazeneca",
        "responsible",
        "development",
        "commercialization",
        "ionis",
        "pharmaceutical",
        "inc",
        "advance",
        "co",
        "may",
        "receive",
        "mln",
        "additional",
        "development",
        "regulatory",
        "milestone",
        "payment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}